CA2850469C - Glycosylated polypeptide and pharmaceutical composition containing same - Google Patents
Glycosylated polypeptide and pharmaceutical composition containing same Download PDFInfo
- Publication number
- CA2850469C CA2850469C CA2850469A CA2850469A CA2850469C CA 2850469 C CA2850469 C CA 2850469C CA 2850469 A CA2850469 A CA 2850469A CA 2850469 A CA2850469 A CA 2850469A CA 2850469 C CA2850469 C CA 2850469C
- Authority
- CA
- Canada
- Prior art keywords
- fmoc
- group
- amino acid
- sugar chain
- glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-218793 | 2011-10-01 | ||
| JP2011218793 | 2011-10-01 | ||
| PCT/JP2012/075262 WO2013047846A1 (ja) | 2011-10-01 | 2012-09-28 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2850469A1 CA2850469A1 (en) | 2013-04-04 |
| CA2850469C true CA2850469C (en) | 2020-07-07 |
Family
ID=47995870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850469A Active CA2850469C (en) | 2011-10-01 | 2012-09-28 | Glycosylated polypeptide and pharmaceutical composition containing same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10358470B2 (enExample) |
| EP (1) | EP2762489B1 (enExample) |
| JP (1) | JP6153470B2 (enExample) |
| KR (1) | KR101979045B1 (enExample) |
| CN (2) | CN104080803B (enExample) |
| AU (1) | AU2012317325B2 (enExample) |
| BR (1) | BR112014007766B1 (enExample) |
| CA (1) | CA2850469C (enExample) |
| DK (1) | DK2762489T3 (enExample) |
| IN (1) | IN2014CN02982A (enExample) |
| MY (1) | MY168902A (enExample) |
| PH (1) | PH12014500694B1 (enExample) |
| RU (1) | RU2636456C2 (enExample) |
| SG (2) | SG10201602076QA (enExample) |
| TW (1) | TWI633115B (enExample) |
| WO (1) | WO2013047846A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN02982A (enExample) | 2011-10-01 | 2015-07-03 | Glytech Inc | |
| AU2014245917B2 (en) * | 2013-03-29 | 2017-09-28 | Glytech, Inc. | Polypeptide having sialylated sugar chains attached thereto |
| CN114685645B (zh) * | 2020-12-30 | 2025-03-21 | 深圳翰宇药业股份有限公司 | 一种索玛鲁肽的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0237019A3 (en) * | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
| AU736993B2 (en) | 1997-01-16 | 2001-08-09 | Novo Nordisk A/S | Practical in vitro sialylation of recombinant glycoproteins |
| DE19717864C2 (de) | 1997-04-23 | 2001-05-17 | Fraunhofer Ges Forschung | Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung |
| DE69936409T2 (de) * | 1998-04-28 | 2008-04-17 | Laboratoires Serono S.A., Coinsins | Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide |
| DK1656952T3 (da) | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| AU766190B2 (en) * | 1998-10-16 | 2003-10-09 | Biogen Idec Ma Inc. | Interferon-beta fusion proteins and uses |
| US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
| WO2001042474A2 (en) * | 1999-12-08 | 2001-06-14 | Amgen, Inc. | Interferon-like molecules and uses thereof |
| US7795002B2 (en) * | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| US20030191291A1 (en) | 2000-09-08 | 2003-10-09 | Kochendoerfer Gerd G. | Synthetic erythropoiesis stimulating proteins |
| EP1366075B1 (en) | 2001-02-27 | 2009-05-27 | Maxygen Aps | New interferon beta-like molecules |
| PL362870A1 (en) | 2001-03-15 | 2004-11-02 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
| CA2469487A1 (en) | 2001-12-11 | 2003-07-03 | Aventis Pasteur | Mutated hiv tat |
| WO2003075944A2 (en) * | 2002-03-12 | 2003-09-18 | Maxygen Aps | Interferon beta-like molecules for treatment of stroke |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| WO2004020468A2 (en) | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| DK1575531T3 (da) * | 2002-09-27 | 2011-11-21 | Biogen Idec Inc | Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta |
| AU2003277088A1 (en) | 2002-10-01 | 2004-04-23 | Xencor, Inc | Interferon variants with improved properties |
| KR100876518B1 (ko) | 2002-12-26 | 2008-12-31 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 아스파라긴 유도체 및 그의 제조방법 |
| WO2005019260A1 (ja) | 2003-08-25 | 2005-03-03 | Toray Industries, Inc. | インターフェロンβ複合体 |
| US20090214472A1 (en) | 2004-03-01 | 2009-08-27 | Enzon Pharmaceuticals Inc. | Interferon-beta polymer conjugates |
| MX2007001589A (es) | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| RU2392963C2 (ru) * | 2004-08-09 | 2010-06-27 | Элиоз Байофарма, Инк. | Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов |
| KR100781666B1 (ko) * | 2004-11-02 | 2007-12-03 | 신영기 | 인간 인터페론-베타 변이체 |
| US20080219952A1 (en) * | 2005-08-26 | 2008-09-11 | Ares Trading S.A. | Process For the Preparation of Glycosylated Interferon Beta |
| US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
| US20080096819A1 (en) | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
| BRPI0813139A8 (pt) | 2007-06-19 | 2019-01-29 | Glytech Inc | peptídeo glp-1 com adição de cadeia oligossacarídea |
| KR101534881B1 (ko) | 2007-07-31 | 2015-07-07 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 펩티드의 제조방법 |
| JP2009242372A (ja) | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
| BRPI0914889A2 (pt) * | 2008-06-17 | 2015-11-24 | Otsuka Chemical Co Ltd | peptídeo glp-1 adicionado de cadeia oligossacarídica |
| CA2733362C (en) * | 2008-08-08 | 2016-10-18 | Universiteit Gent | Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof |
| AU2009283678B2 (en) * | 2008-08-19 | 2014-01-16 | Glytech, Inc. | Glycoprotein production method and screening method |
| WO2012051615A1 (en) | 2010-10-15 | 2012-04-19 | Transgenrx, Inc. | Novel vectors for production of glycosylated interferon |
| JP5925760B2 (ja) | 2011-03-10 | 2016-05-25 | 株式会社糖鎖工学研究所 | シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド |
| ES2774284T3 (es) | 2011-06-29 | 2020-07-20 | Kyowa Kirin Co Ltd | Método para purificar antitrombina |
| IN2014CN02982A (enExample) | 2011-10-01 | 2015-07-03 | Glytech Inc |
-
2010
- 2010-08-18 IN IN2982CHN2014 patent/IN2014CN02982A/en unknown
-
2012
- 2012-09-28 CN CN201280058952.8A patent/CN104080803B/zh not_active Expired - Fee Related
- 2012-09-28 EP EP12836998.0A patent/EP2762489B1/en active Active
- 2012-09-28 CA CA2850469A patent/CA2850469C/en active Active
- 2012-09-28 RU RU2014116550A patent/RU2636456C2/ru active
- 2012-09-28 PH PH1/2014/500694A patent/PH12014500694B1/en unknown
- 2012-09-28 BR BR112014007766-5A patent/BR112014007766B1/pt not_active IP Right Cessation
- 2012-09-28 SG SG10201602076QA patent/SG10201602076QA/en unknown
- 2012-09-28 DK DK12836998.0T patent/DK2762489T3/en active
- 2012-09-28 MY MYPI2014000925A patent/MY168902A/en unknown
- 2012-09-28 SG SG11201401071YA patent/SG11201401071YA/en unknown
- 2012-09-28 KR KR1020147010631A patent/KR101979045B1/ko not_active Expired - Fee Related
- 2012-09-28 AU AU2012317325A patent/AU2012317325B2/en not_active Ceased
- 2012-09-28 JP JP2013536471A patent/JP6153470B2/ja not_active Expired - Fee Related
- 2012-09-28 US US14/347,222 patent/US10358470B2/en active Active
- 2012-09-28 WO PCT/JP2012/075262 patent/WO2013047846A1/ja not_active Ceased
- 2012-09-28 CN CN201811042210.1A patent/CN109134642A/zh active Pending
- 2012-10-01 TW TW101136177A patent/TWI633115B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500694B1 (en) | 2020-01-31 |
| IN2014CN02982A (enExample) | 2015-07-03 |
| TW201321404A (zh) | 2013-06-01 |
| TWI633115B (zh) | 2018-08-21 |
| EP2762489B1 (en) | 2018-03-28 |
| SG10201602076QA (en) | 2016-04-28 |
| US10358470B2 (en) | 2019-07-23 |
| BR112014007766A2 (pt) | 2017-04-04 |
| KR20140095051A (ko) | 2014-07-31 |
| SG11201401071YA (en) | 2014-08-28 |
| RU2636456C2 (ru) | 2017-11-23 |
| CN104080803A (zh) | 2014-10-01 |
| WO2013047846A1 (ja) | 2013-04-04 |
| EP2762489A4 (en) | 2015-05-06 |
| JP6153470B2 (ja) | 2017-06-28 |
| AU2012317325A1 (en) | 2014-04-17 |
| MY168902A (en) | 2018-12-04 |
| JPWO2013047846A1 (ja) | 2015-03-30 |
| EP2762489A9 (en) | 2015-02-11 |
| AU2012317325B2 (en) | 2016-10-06 |
| CN104080803B (zh) | 2020-08-04 |
| EP2762489A1 (en) | 2014-08-06 |
| BR112014007766B1 (pt) | 2022-05-10 |
| RU2014116550A (ru) | 2015-10-27 |
| DK2762489T3 (en) | 2018-07-02 |
| PH12014500694A1 (en) | 2014-05-12 |
| CA2850469A1 (en) | 2013-04-04 |
| US20140369964A1 (en) | 2014-12-18 |
| KR101979045B1 (ko) | 2019-05-15 |
| CN109134642A (zh) | 2019-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102083854A (zh) | 附加了糖链的glp-1肽 | |
| JP5517620B2 (ja) | ペプチドの製造方法 | |
| CN104936613B (zh) | 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法 | |
| US20120114595A1 (en) | Sugar chain-added ailim extracellular domain and method for producing same | |
| AU2012317325B2 (en) | Glycosylated polypeptide and pharmaceutical composition containing same | |
| CN104334574B (zh) | 附加唾液酸化糖链的多肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251205 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260320 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260619 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260801 |